[1] |
熊清芳, 黄平, 赵磊, 等. 慢性乙型肝炎患者CD8+记忆T细胞的检测分析[J]. 中华临床医师杂志(电子版), 2014, 8(16):2960-2963.
|
[2] |
冯燚源, 王安生, 吴春成, 等. 鼻腔Castleman病1例[J]. 中国耳鼻咽喉颅底外科杂志, 2022, 28(3):99-101.
|
[3] |
Sopfe J, Endres A, Campbell K, et al. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study[J]. Pediatr Blood Cancer, 2019, 66(5): e27613.
|
[4] |
孟庆磊, 李白, 王一铭, 等. 儿童Castleman病临床病理和治疗分析[J]. 中华儿科杂志, 2022, 60(3):227-231.
|
[5] |
Haap M, Wiefels J, Horger M, et al. Clinical, laboratory and imaging findings in Castleman's disease-The subtype decides[J]. Blood Rev, 2018, 32(3): 225-234.
|
[6] |
李理, 马宏浩, 魏昂, 等. 儿童重症Castleman病变异型POEMS综合征1例[J]. 中国临床案例成果数据库, 2023, 5(1):E00435-E00435.
|
[7] |
陈健聪, 吴锡平. 多中心型混合型Castleman病1例[J]. 中国实用儿科杂志, 2018, 33(5):396-398.
|
[8] |
赵扬, 孙岩峰, 苗丽霞, 等. 儿童腹膜后Castleman病一例[J]. 中华儿科杂志, 2018, 56(1):62-63.
|
[9] |
薛玉娟, 张乐萍, 程翼飞. 儿童多中心型混合型Castleman病一例[J]. 中华血液学杂志, 2016, 37(10):869-869.
|
[10] |
周建文, 管玉洁, 李妍, 等. 以反应性浆细胞增多症及生长发育落后为主要表现的儿童Castleman病1例[J]. 中华医学杂志, 2023, 103(35):2816-2817.
|
[11] |
罗丽娟, 殷蕾, 周云芳, 等. 儿童多中心型Castleman病一例报道并文献复习[J]. 中国小儿急救医学, 2016, 23(9):645-646.
|
[12] |
Hoffmann C, Hentrich M, Tiemann M, et al. Recent advances in Castleman disease[J]. Oncol Res Treat, 2022, 45(11): 693-704.
|
[13] |
Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; Case No. 40351[J]. N Engl J Med, 1954, 251(10): 396-400.
|
[14] |
Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133(16): 1720-1728.
doi: 10.1182/blood-2018-11-884577
pmid: 30760451
|
[15] |
DeMarsh SJ, Kendel NE, Bacha C, et al. Storming the castle: A case report of multi-system dysregulation in a child with Castleman disease[J]. Clin Case Rep, 2022, 10(2): e05491.
|
[16] |
Zhang MY, Jia MN, Chen J, et al. UCD with MCD-like inflammatory state: Surgical excision is highly effective[J]. Blood Adv, 2021, 5(1): 122-128.
|
[17] |
van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2014, 15(9): 966-974.
doi: 10.1016/S1470-2045(14)70319-5
pmid: 25042199
|
[18] |
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132(20): 2115-2124.
doi: 10.1182/blood-2018-07-862334
pmid: 30181172
|
[19] |
van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease[J]. Blood Adv, 2020, 4(23): 6039-6050.
doi: 10.1182/bloodadvances.2020003334
pmid: 33284946
|
[20] |
Sacks D, Baxter B, Campbell BCV, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke[J]. Int J Stroke, 2018, 13(6): 612-632.
doi: 10.1177/1747493018778713
pmid: 29786478
|
[21] |
Chan KL, Lade S, Prince HM, et al. Update and new approaches in the treatment of Castleman disease[J]. J Blood Med, 2016, 7: 145-158.
|
[22] |
Galeotti C, Tran TA, Franchi-Abella S, et al. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: Case report[J]. J Pediatr Hematol Oncol, 2008, 30(12): 920-924.
doi: 10.1097/MPH.0b013e31818ab31f
pmid: 19131781
|